British stocks tumbled as pharmaceutical shares slumped due to escalating tariffs between the U.S. and China. The FTSE 100 ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

The PA news agency looks at which sectors will be most affected by the plans and what it means for businesses and households.

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the treatment of uncomplicated urinary tract infections (UTIs) in women aged ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

Robert F. Kennedy Jr. is set to significantly cut the size of HHS, reshaping the nation’s health agencies and closing ...

Blujepa interferes with that process, which prevents the bacteria from replicating and producing more bacteria that can infect cells. Read More: Menopause Is Finally Going Mainstream Tony Wood, chief ...